Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer.

H H Hansen, M Rørth

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Combination chemotherapy, including etoposide and cisplatin, remains the standard for small cell lung cancer, offering high response rates. Optimal treatment duration and scheduling, particularly for etoposide, are crucial for improving long-term survival in lung cancer patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effects of alternative feed additives to medicinal zinc oxide on productivity, diarrhoea incidence and gut development in weaned piglets.

    Animal : an international journal of animal bioscience·2020
    Same author

    Evaluation of the feeding value of Dichrostachys cinerea pods for fattening pigs in Cuba.

    Tropical animal health and production·2017
    Same author

    High plasma triglyceride levels strongly correlate with low kisspeptin in the arcuate nucleus of male rats.

    Endocrine regulations·2015
    Same author

    Technical note: In vitro total gas and methane production measurements from closed or vented rumen batch culture systems.

    Journal of dairy science·2014
    Same author

    Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.

    Developmental neuroscience·2010
    Same author

    The medullary nail presentation of a new type and report of a case.

    Archives of surgery (Chicago, Ill. : 1920)·2010
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles

    Area of Science:

    • Oncology
    • Medical Chemotherapy

    Background:

    • Small cell lung cancer (SCLC) treatment relies heavily on combination chemotherapy.
    • Etoposide and cisplatin derivatives are increasingly used in initial SCLC therapy.
    • Current treatments achieve high response rates but long-term survival remains a challenge.

    Purpose of the Study:

    • To review current chemotherapy standards for small cell lung cancer.
    • To discuss optimal treatment duration and scheduling for etoposide.
    • To highlight the experimental nature of treatments for other lung cancer types.

    Main Methods:

    • Review of existing studies on combination chemotherapy for SCLC.
    • Analysis of response rates, duration, and survival data.
    • Evaluation of treatment scheduling and duration, including etoposide dose scheduling.

    Related Experiment Videos

    Main Results:

    • Combination chemotherapy yields 80-90% response rates in SCLC, with median survival of 11-16 months.
    • Continuous etoposide treatment for 5+ days appears superior.
    • Treatments for non-small cell lung cancer types remain largely experimental.

    Conclusions:

    • Combination chemotherapy is the backbone for SCLC, but optimal duration is uncertain.
    • Further improvements in systemic and local treatments are needed for lung cancer.
    • Induction chemotherapy before irradiation shows promise for locoregional disease.